Fig. 2: Characteristics of response and progression during the study for the 25 patients treated with blinatumomab.
R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. Source data are provided as a Source Data file.
Fig. 2: Characteristics of response and progression during the study for the 25 patients treated with blinatumomab. | Nature Communications
